Global NanoBioTechnology (NBT) 麻豆原创 Research Report 2023

Publication ID:

PB504233903

Publication Date:

April 17, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Nano biotechnology combines nano technology and biotechnology including special physicochemical and biological properties of nanostructures and their applications in numerous fieldslike medicine and agriculture. Nanobiotechnology is one of the most promising technologies in the 21st century. It plays a major role in developing and implementing many useful tools in the study of life. Its application in medicine involves disease diagnosis, target-specific drug delivery and molecular imaging. It also has application in agriculture and food. The factors such as increasing demand for the innovative drug in the pharmaceutical industry, rise in the application of nano biotechnology electronics, energy production and biomaterials and increased research & development investment are the key drivers of the global nano biotechnology market.
Highlights
The global NanoBioTechnology (NBT) market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for NanoBioTechnology (NBT) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for NanoBioTechnology (NBT) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for NanoBioTechnology (NBT) in Pharmaceuticals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of NanoBioTechnology (NBT) include Ablynx (Belgium), Nami Therapeutics (US), Celgene Corporation (US), Nanophase Technologies Corporation (US), Sigma-Aldrich (US), SkyePharma Pharmaceuticals (France), Nano Bridging Molecules SA (Switzerland), XanTecbioanalytics GmbH (Germany) and Nanobiotix(France), etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for NanoBioTechnology (NBT), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding NanoBioTechnology (NBT).
The NanoBioTechnology (NBT) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global NanoBioTechnology (NBT) market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the NanoBioTechnology (NBT) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Ablynx (Belgium)
Nami Therapeutics (US)
Celgene Corporation (US)
Nanophase Technologies Corporation (US)
Sigma-Aldrich (US)
SkyePharma Pharmaceuticals (France)
Nano Bridging Molecules SA (Switzerland)
XanTecbioanalytics GmbH (Germany)
Nanobiotix(France)
Dabur Pharma (India)
Segment by Type
0-10 nm
10-100 nm
Segment by Application
Pharmaceuticals
Medical Research
Food and Agriculture
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of NanoBioTechnology (NBT) companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global NanoBioTechnology (NBT) 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 0-10 nm
1.2.3 10-100 nm
1.3 麻豆原创 by Application
1.3.1 Global NanoBioTechnology (NBT) 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceuticals
1.3.3 Medical Research
1.3.4 Food and Agriculture
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global NanoBioTechnology (NBT) 麻豆原创 Perspective (2018-2029)
2.2 NanoBioTechnology (NBT) Growth Trends by Region
2.2.1 Global NanoBioTechnology (NBT) 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 NanoBioTechnology (NBT) Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 NanoBioTechnology (NBT) Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 NanoBioTechnology (NBT) 麻豆原创 Dynamics
2.3.1 NanoBioTechnology (NBT) Industry Trends
2.3.2 NanoBioTechnology (NBT) 麻豆原创 Drivers
2.3.3 NanoBioTechnology (NBT) 麻豆原创 Challenges
2.3.4 NanoBioTechnology (NBT) 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top NanoBioTechnology (NBT) Players by Revenue
3.1.1 Global Top NanoBioTechnology (NBT) Players by Revenue (2018-2023)
3.1.2 Global NanoBioTechnology (NBT) Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global NanoBioTechnology (NBT) 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by NanoBioTechnology (NBT) Revenue
3.4 Global NanoBioTechnology (NBT) 麻豆原创 Concentration Ratio
3.4.1 Global NanoBioTechnology (NBT) 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by NanoBioTechnology (NBT) Revenue in 2022
3.5 NanoBioTechnology (NBT) Key Players Head office and Area Served
3.6 Key Players NanoBioTechnology (NBT) Product Solution and Service
3.7 Date of Enter into NanoBioTechnology (NBT) 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 NanoBioTechnology (NBT) Breakdown Data by Type
4.1 Global NanoBioTechnology (NBT) Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global NanoBioTechnology (NBT) Forecasted 麻豆原创 Size by Type (2024-2029)
5 NanoBioTechnology (NBT) Breakdown Data by Application
5.1 Global NanoBioTechnology (NBT) Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global NanoBioTechnology (NBT) Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America NanoBioTechnology (NBT) 麻豆原创 Size (2018-2029)
6.2 North America NanoBioTechnology (NBT) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America NanoBioTechnology (NBT) 麻豆原创 Size by Country (2018-2023)
6.4 North America NanoBioTechnology (NBT) 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe NanoBioTechnology (NBT) 麻豆原创 Size (2018-2029)
7.2 Europe NanoBioTechnology (NBT) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe NanoBioTechnology (NBT) 麻豆原创 Size by Country (2018-2023)
7.4 Europe NanoBioTechnology (NBT) 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific NanoBioTechnology (NBT) 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific NanoBioTechnology (NBT) 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific NanoBioTechnology (NBT) 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific NanoBioTechnology (NBT) 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America NanoBioTechnology (NBT) 麻豆原创 Size (2018-2029)
9.2 Latin America NanoBioTechnology (NBT) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America NanoBioTechnology (NBT) 麻豆原创 Size by Country (2018-2023)
9.4 Latin America NanoBioTechnology (NBT) 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa NanoBioTechnology (NBT) 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa NanoBioTechnology (NBT) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa NanoBioTechnology (NBT) 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa NanoBioTechnology (NBT) 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ablynx (Belgium)
11.1.1 Ablynx (Belgium) Company Detail
11.1.2 Ablynx (Belgium) Business Overview
11.1.3 Ablynx (Belgium) NanoBioTechnology (NBT) Introduction
11.1.4 Ablynx (Belgium) Revenue in NanoBioTechnology (NBT) Business (2018-2023)
11.1.5 Ablynx (Belgium) Recent Development
11.2 Nami Therapeutics (US)
11.2.1 Nami Therapeutics (US) Company Detail
11.2.2 Nami Therapeutics (US) Business Overview
11.2.3 Nami Therapeutics (US) NanoBioTechnology (NBT) Introduction
11.2.4 Nami Therapeutics (US) Revenue in NanoBioTechnology (NBT) Business (2018-2023)
11.2.5 Nami Therapeutics (US) Recent Development
11.3 Celgene Corporation (US)
11.3.1 Celgene Corporation (US) Company Detail
11.3.2 Celgene Corporation (US) Business Overview
11.3.3 Celgene Corporation (US) NanoBioTechnology (NBT) Introduction
11.3.4 Celgene Corporation (US) Revenue in NanoBioTechnology (NBT) Business (2018-2023)
11.3.5 Celgene Corporation (US) Recent Development
11.4 Nanophase Technologies Corporation (US)
11.4.1 Nanophase Technologies Corporation (US) Company Detail
11.4.2 Nanophase Technologies Corporation (US) Business Overview
11.4.3 Nanophase Technologies Corporation (US) NanoBioTechnology (NBT) Introduction
11.4.4 Nanophase Technologies Corporation (US) Revenue in NanoBioTechnology (NBT) Business (2018-2023)
11.4.5 Nanophase Technologies Corporation (US) Recent Development
11.5 Sigma-Aldrich (US)
11.5.1 Sigma-Aldrich (US) Company Detail
11.5.2 Sigma-Aldrich (US) Business Overview
11.5.3 Sigma-Aldrich (US) NanoBioTechnology (NBT) Introduction
11.5.4 Sigma-Aldrich (US) Revenue in NanoBioTechnology (NBT) Business (2018-2023)
11.5.5 Sigma-Aldrich (US) Recent Development
11.6 SkyePharma Pharmaceuticals (France)
11.6.1 SkyePharma Pharmaceuticals (France) Company Detail
11.6.2 SkyePharma Pharmaceuticals (France) Business Overview
11.6.3 SkyePharma Pharmaceuticals (France) NanoBioTechnology (NBT) Introduction
11.6.4 SkyePharma Pharmaceuticals (France) Revenue in NanoBioTechnology (NBT) Business (2018-2023)
11.6.5 SkyePharma Pharmaceuticals (France) Recent Development
11.7 Nano Bridging Molecules SA (Switzerland)
11.7.1 Nano Bridging Molecules SA (Switzerland) Company Detail
11.7.2 Nano Bridging Molecules SA (Switzerland) Business Overview
11.7.3 Nano Bridging Molecules SA (Switzerland) NanoBioTechnology (NBT) Introduction
11.7.4 Nano Bridging Molecules SA (Switzerland) Revenue in NanoBioTechnology (NBT) Business (2018-2023)
11.7.5 Nano Bridging Molecules SA (Switzerland) Recent Development
11.8 XanTecbioanalytics GmbH (Germany)
11.8.1 XanTecbioanalytics GmbH (Germany) Company Detail
11.8.2 XanTecbioanalytics GmbH (Germany) Business Overview
11.8.3 XanTecbioanalytics GmbH (Germany) NanoBioTechnology (NBT) Introduction
11.8.4 XanTecbioanalytics GmbH (Germany) Revenue in NanoBioTechnology (NBT) Business (2018-2023)
11.8.5 XanTecbioanalytics GmbH (Germany) Recent Development
11.9 Nanobiotix(France)
11.9.1 Nanobiotix(France) Company Detail
11.9.2 Nanobiotix(France) Business Overview
11.9.3 Nanobiotix(France) NanoBioTechnology (NBT) Introduction
11.9.4 Nanobiotix(France) Revenue in NanoBioTechnology (NBT) Business (2018-2023)
11.9.5 Nanobiotix(France) Recent Development
11.10 Dabur Pharma (India)
11.10.1 Dabur Pharma (India) Company Detail
11.10.2 Dabur Pharma (India) Business Overview
11.10.3 Dabur Pharma (India) NanoBioTechnology (NBT) Introduction
11.10.4 Dabur Pharma (India) Revenue in NanoBioTechnology (NBT) Business (2018-2023)
11.10.5 Dabur Pharma (India) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Ablynx (Belgium)
Nami Therapeutics (US)
Celgene Corporation (US)
Nanophase Technologies Corporation (US)
Sigma-Aldrich (US)
SkyePharma Pharmaceuticals (France)
Nano Bridging Molecules SA (Switzerland)
XanTecbioanalytics GmbH (Germany)
Nanobiotix(France)
Dabur Pharma (India)

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.